Companies Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals (ETON): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Eton Pharmaceuticals, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $1,747,045FY2023
- $2,411,923FY2024
- $2,914,489FY2025
CEO total pay was $2,914,489 in fiscal 2025, up from $2,411,923 in fiscal 2024.
FY2025: salary $712,433 · bonus $0 · stock awards $936,052 · option awards $893,712
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Sean Brynjelsen | $712,433 | $0 | $936,052 | $893,712 | $354,792 | $0 | $17,500 | $2,914,489 |
| President and Chief Executive Officer | ||||||||
| James Gruber | 460,460 | 0 | 336,388 | 321,172 | 171,982 | 0 | 108,066 | 1,398,068 |
| Chief Financial Officer | ||||||||
| David Krempa | 460,460 | 0 | 336,388 | 321,172 | 171,982 | 0 | 104,743 | 1,394,745 |
| Chief Business Officer | ||||||||
| Ipek Erdogan-Trinkaus | 402,722 | 0 | 0 | 0 | 150,417 | 0 | 22,153 | 575,292 |
| Chief Commercial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Sean Brynjelsen | $2,914,489 | $2,411,923 | $1,747,045 | ↑ +502,566 |
| James Gruber | 1,398,068 | 1,075,080 | 785,140 | ↑ +322,988 |
| David Krempa | 1,394,745 | 1,325,083 | 719,080 | ↑ +69,662 |
| Ipek Erdogan-Trinkaus | 575,292 | 775,488 | — | ↓ −200,196 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company considers compensation for comparable positions in the market, historical compensation levels, individual performance, and the desire to motivate employees to achieve short- and long-term results in the best interests of stockholders.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Radford, an Aon company |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Sean Brynjelsen | RSA | — | — | — | 1,000,000 | — | — |
Vehicle mix — grant-date fair value by award type
Grant-level vehicle detail not disclosed.
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Ipek Erdogan-Trinkaus | RSU | 6,020 | — | $101,798 |
| David Krempa | Option | 6,595 | 3.78 | — |
| James Gruber | RSU | 10,000 | — | 169,100 |
| David Krempa | RSU | 10,000 | — | 169,100 |
| David Krempa | Option | 21,666 | 3.47 | — |
| James Gruber | Option | 25,000 | 3.81 | — |
| James Gruber | RSU | 25,876 | — | 438,563 |
| David Krempa | RSU | 25,876 | — | 438,563 |
| Sean Brynjelsen | RSU | 27,500 | — | 465,025 |
| James Gruber | Option | 29,192 | 3.47 | — |
| James Gruber | Option | 29,771 | 13 | — |
| David Krempa | Option | 29,771 | 13 | — |
| David Krempa | RSU | 31,566 | — | 533,781 |
| Ipek Erdogan-Trinkaus | Option | 56,250 | 12.46 | — |
| Sean Brynjelsen | RSU | 72,004 | — | 1,217,588 |
| James Gruber | Option | 78,367 | 4.42 | — |
| David Krempa | Option | 78,367 | 4.42 | — |
| Sean Brynjelsen | Option | 82,841 | 13 | — |
| Sean Brynjelsen | Option | 102,195 | 3.47 | — |
| Sean Brynjelsen | Option | 237,593 | 4.42 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Norbert G. Riedel, Ph.DIndependent · Board Chair · Audit · Compensation · Nominating and Corporate Governance (Chair) | $123,672 | — | $194,375 | — | — | $318,047 |
| Paul V. MaierIndependent · Audit (Chair) · Nominating and Corporate Governance · Compensation | 83,468 | — | 194,375 | — | — | 277,843 |
| Charles J. CasamentoIndependent · Audit · Compensation (Chair) · Nominating and Corporate Governance | 80,764 | — | 194,375 | — | — | 275,139 |
| Jenn AdamsIndependent · Audit · Compensation · Nominating and Corporate Governance | 72,652 | — | 194,375 | — | — | 267,027 |
| Sean E. BrynjelsenEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | — |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | — |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $360,556 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $360,556 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Eton Pharmaceuticals as a peer
Companies that benchmark against ETON
2 companies name ETON as a compensation peer
- AYTU BIOPHARMA, INCAYTUFY2026
- SIGA TECHNOLOGIES INCSIGAFY2025
Each company listed discloses ETON in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ETON in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Eton Pharmaceuticals, Inc. | 2025 | Sean Brynjelsen | $712,433 | $936,052 | $893,712 | $354,792 | $2,914,489 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-06-11 | 9,170,839 | 553,043 | 63,364 | 93.7% | Passed |
| 2023 | 2023-06-13 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2024 | 2024-06-11 | 93.7%a |
| 2023 | 2023-06-13 | —b |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have the effect of a vote "against" (i) the advisory vote on executive compensation (ii) the appointment of KMJ Corbin & Company LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.”.
b. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (15 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Sean Brynjelsen. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · page 18. As printed: 2,914,489. View filing ↗
- Section 01, James Gruber. DEF 14A, filed 2026-04-24. Section “Executive Compensation”. As printed: 1,398,068. View filing ↗
- Section 01, David Krempa. DEF 14A, filed 2026-04-24. Section “Executive Compensation”. As printed: 1,394,745. View filing ↗
- Section 01, Ipek Erdogan-Trinkaus. DEF 14A, filed 2026-04-24. Section “Executive Compensation”. As printed: 575,292. View filing ↗
- Section 03, Sean Brynjelsen RSA. DEF 14A, filed 2026-04-24. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 08, Norbert G. Riedel, Ph.D. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 318,047. View filing ↗
- Section 08, Paul V. Maier. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 277,843. View filing ↗
- Section 08, Charles J. Casamento. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 275,139. View filing ↗
- Section 08, Jenn Adams. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 267,027. View filing ↗
- Section 08, Sean E. Brynjelsen. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-11. Item 5.07 · say-on-pay result. As reported: 93.7% (votes for as printed: 9,170,839). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-13. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 360,556 + equity 0 + all other 0 = 360,556, summed across the director compensation table rows.
- Eton Pharmaceuticals, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Eton Pharmaceuticals, Inc.'s own proxy. As printed: 2,914,489. View filing ↗